3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Phase 2
3
Phase NA
2
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
70
INDUSTRY
59
NIH
8
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Breast Neoplasms
9
Central Nervous System Neoplasms
8
Multiple Myeloma
7
Lung Neoplasms
7
Leukemia, Myeloid, Acute
6
Ovarian Neoplasms
5
Uterine Cervical Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Non-Hodgkin
4
Leukemia
4
Gliosarcoma
4
Glioblastoma
4
Burkitt Lymphoma
4
Squamous Cell Carcinoma of Head and Neck
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Congenital Abnormalities
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Recurrence
2
Radiation Injuries
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Oligodendroglioma
2
Neuroblastoma
2
Myelodysplastic Syndromes
2
Lymphoma
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Monocytic, Acute
2
Interventions
Sirolimus
1
Lenalidomide
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
NETWORK
×
Hematologic Neoplasms
×
Clear all
NCT01460420
2017-07-06
EMN-alloRIC
European Myeloma Network B.V.
Phase 1/2
Completed
49 enrolled